难治性自身免疫性脑炎的新可行治疗方法：低剂量白细胞介素-2
New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2.
作者信息
Lim Jung-Ah, Lee Soon-Tae, Moon Jangsup, Jun Jin-Sun, Park Byeong-Su, Byun Jung-Ick, Sunwoo Jun-Sang, Park Kyung-Il, Jung Keun-Hwa, Jung Ki-Young, Lee Sang Kun, Chu Kon
机构信息
Department of Neurology, Comprehensive Epilepsy Center, Laboratory for Neurotherapeutics, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.
Department of Neurology, Comprehensive Epilepsy Center, Laboratory for Neurotherapeutics, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Department of Neurology, Kyung Hee University Hospital at Gangdong, Seoul, South Korea.
出版信息
J Neuroimmunol. 2016 Oct 15;299:107-111. doi: 10.1016/j.jneuroim.2016.09.001. Epub 2016 Sep 3.
Low-dose interleukin-2 (IL-2) restores the balance of regulatory and effector T cells. We aimed to determine the feasibility of low-dose IL-2 as a treatment for refractory autoimmune encephalitis (AE). Ten patients who had received low-dose IL-2 were retrospectively identified. We observed an improvement in the modified Rankin Scale scores of six patients at the last follow-up compared with the scores at the initiation of low-dose IL-2 (p=0.014). One patient experienced treatment-related grade 3 neutropenia. Overall, low-dose IL-2 is a feasible and relatively safe treatment for AE patients who are refractory to the first- and second-line immunotherapies.
低剂量白细胞介素-2（IL-2）可恢复调节性T细胞和效应性T细胞之间的平衡。我们旨在确定低剂量IL-2治疗难治性自身免疫性脑炎（AE）的可行性。回顾性纳入10例接受低剂量IL-2治疗的患者。与低剂量IL-2治疗开始时相比，6例患者在末次随访时改良Rankin量表评分有所改善（p = 0.014）。1例患者出现3级治疗相关中性粒细胞减少。总体而言，对于一线和二线免疫治疗难治的AE患者，低剂量IL-2是一种可行且相对安全的治疗方法。
Zotero 插件